Madrigal Pharmaceuticals, Inc.
NASDAQ:MDGL
319.69 (USD) • At close January 3, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Madrigal Pharmaceuticals, Inc. |
Symbool | MDGL |
Munteenheid | USD |
Prijs | 319.69 |
Beurswaarde | 6,972,566,776 |
Dividendpercentage | 0% |
52-weken bereik | 168.25 - 368.29 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. William J. Sibold |
Website | https://www.madrigalpharma.com |
An error occurred while fetching data.
Over Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)